84,517 Shares in LeMaitre Vascular, Inc. (NASDAQ:LMAT) Bought by Rockefeller Capital Management L.P.

Rockefeller Capital Management L.P. purchased a new position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 84,517 shares of the medical instruments supplier's stock, valued at approximately $7,787,000. Rockefeller Capital Management L.P. owned 0.38% of LeMaitre Vascular as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of LMAT. Allspring Global Investments Holdings LLC raised its stake in shares of LeMaitre Vascular by 48.2% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 13,321 shares of the medical instruments supplier's stock worth $1,227,000 after acquiring an additional 4,330 shares in the last quarter. Barclays PLC boosted its position in shares of LeMaitre Vascular by 394.5% in the 3rd quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier's stock worth $3,396,000 after purchasing an additional 29,180 shares in the last quarter. Compass Planning Associates Inc purchased a new position in LeMaitre Vascular during the 4th quarter worth $567,000. Invesco Ltd. raised its stake in LeMaitre Vascular by 50.5% in the fourth quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier's stock valued at $16,124,000 after buying an additional 58,720 shares during the last quarter. Finally, Teacher Retirement System of Texas raised its position in shares of LeMaitre Vascular by 31.8% in the 4th quarter. Teacher Retirement System of Texas now owns 101,851 shares of the medical instruments supplier's stock valued at $9,385,000 after purchasing an additional 24,586 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Stock Up 1.7 %

LMAT traded up $1.43 during trading on Tuesday, reaching $86.15. The company's stock had a trading volume of 122,826 shares, compared to its average volume of 160,850. The company has a market cap of $1.94 billion, a price-to-earnings ratio of 47.08, a PEG ratio of 2.22 and a beta of 0.89. The firm has a fifty day simple moving average of $87.40 and a two-hundred day simple moving average of $93.42. LeMaitre Vascular, Inc. has a 1 year low of $62.50 and a 1 year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share for the quarter, meeting the consensus estimate of $0.49. The firm had revenue of $55.81 million for the quarter, compared to analysts' expectations of $55.99 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. As a group, equities analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 27th. Stockholders of record on Thursday, March 13th were paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.93%. This is an increase from LeMaitre Vascular's previous quarterly dividend of $0.16. The ex-dividend date was Thursday, March 13th. LeMaitre Vascular's payout ratio is 41.24%.

Insider Transactions at LeMaitre Vascular

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of LeMaitre Vascular stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total value of $164,979.08. Following the completion of the transaction, the insider now directly owns 5,564 shares of the company's stock, valued at $456,915.68. The trade was a 26.53 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 10.79% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Barrington Research lowered shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Oppenheimer cut LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Wells Fargo & Company began coverage on LeMaitre Vascular in a report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 target price for the company. Finally, Lake Street Capital lifted their price objective on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Five research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, LeMaitre Vascular has a consensus rating of "Moderate Buy" and an average target price of $95.25.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.